key: cord-0260588-r9sly5v8 authors: Kojima, N.; Brobeck, M.; Slepnev, V.; Klausner, J. D. title: A national survey of early treatment seeking behavior among those with incident SARS-CoV-2 infection date: 2022-01-14 journal: nan DOI: 10.1101/2022.01.13.22269022 sha: 33ac01469540063e91a2b880a9bdce201ff47a8e doc_id: 260588 cord_uid: r9sly5v8 Background: Despite effective means to treat SARS-CoV-2 infection, the early treatment seeking behavior of those newly diagnosed with infection is not clear. Methods: We surveyed users of a national SARS-CoV-2 testing company to assess the frequency and correlates of early treatment seeking behavior for a positive test result. We recruited adults (18 years or older) who had tested positive for SARS-CoV-2 by PCR at a large clinical laboratory. To be eligible, individuals had to have a positive test result within 7 days of enrollment. Surveys were anonymous and voluntary. We collected data on demographic characteristics, general health care access and utilization, awareness of treatment for COVID-19, treatment seeking behavior, and treatments received. Descriptive statistics and odds ratios (OR) with 95% confidence intervals (95% CI) were calculated on StataSE. Results: Participants were surveyed from 3-7 January 2022: among the 15,991 who viewed a survey request, 7,647 individuals were eligible and provided responses. The median age of a respondent was 42 years (interquartile range: 32 to 54), 68.9% of respondents were women, and respondents represented 33 different states, districts, and territories. Among respondents, 23.1% reported they had sought treatment or medical advice for their current COVID-19 diagnosis. Of those who were very aware of treatment for COVID-19, 31.0% sought treatment versus 16.7% who were unaware (p-value< 0.001). The odds of treatment seeking behavior were higher for those that were contacted by a medical professional after their diagnosis (OR: 4.57 [95% CI: 3.89 to 5.37]), those with a primary doctor (OR: 2.94 [95% CI: 2.52 to 3.43]), those who self-measured their oxygen saturation (OR: 2.53 [95% CI: 2.25 to 2.84]), and those over 65 years of age (OR: 2.36 [95% CI: 2.02 to 2.76]). There was no difference in those seeking treatment based on heritage, ethnicity, prior COVID-19 diagnosis, state political affiliation, or vaccination status. The odds of seeking treatment were lower among men (OR: 0.88 [95% CI: 0.78 to 0.99]) and those without insurance (OR: 0.62 [95% CI: 0.52 to 0.72]). The most common treatment locations were clinics and most common treatments were Vitamin C, Vitamin D, Zinc, Tylenol, and NSAIDs. Conclusion: More public outreach is needed to raise awareness of the benefits of treatment for COVID-19. We found that people who were more aware about treatment for COVID-19 were more likely to seek medical advice or therapy. Efforts to increase awareness might increase early treatment for SARS-CoV-2 infection. Increased outreach with treatment facilitation from medical professionals and/or public health staff to those with newly detected SARS-CoV-2 infections, particularly among those at higher-risk of complications, might also be helpful. Methods: We surveyed users of a national SARS-CoV-2 testing company to assess the 28 frequency and correlates of early treatment seeking behavior for a positive test result. 29 We recruited adults (18 years or older) who had tested positive for SARS-CoV-2 by 30 PCR at a large clinical laboratory. To be eligible, individuals had to have a positive test 31 result within 7 days of enrollment. Surveys were anonymous and voluntary. We 32 collected data on demographic characteristics, general health care access and 33 utilization, awareness of treatment for COVID-19, treatment seeking behavior, and 34 treatments received. Descriptive statistics and odds ratios (OR) with 95% confidence 35 intervals (95% CI) were calculated on StataSE. 36 Results: Participants were surveyed from 3-7 January 2022: among the 15,991 who 37 viewed a survey request, 7,647 individuals were eligible and provided responses. to 0.72]). The most common treatment locations were clinics and most common 52 treatments were Vitamin C, Vitamin D, Zinc, Tylenol, and NSAIDs. 53 Conclusion: More public outreach is needed to raise awareness of the benefits of 54 treatment for COVID-19. We found that people who were more aware about treatment 55 for COVID-19 were more likely to seek medical advice or therapy. Efforts to increase 56 awareness might increase early treatment for SARS-CoV-2 infection. Increased 57 outreach with treatment facilitation from medical professionals and/or public health staff 58 to those with newly detected SARS-CoV-2 infections, particularly among those at 59 higher-risk of complications, might also be helpful. 60 61 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 14, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 14, 2022. were clinics and most common treatments were Vitamin C, Vitamin D, Zinc, Tylenol, 101 and NSAIDs (Table 2) . 102 Due to the timing of the survey, infection was most likely due to the Omicron variant of 104 SARS-CoV-2, which might be less severe in those with prior immunity. 5 The most 105 commonly used treatments were over-the-counter medications for symptom relief. Few 106 had received therapies known to reduce risk of disease progression. 4,6 There were also 107 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.13.22269022 doi: medRxiv preprint 6 continued reports of non-beneficial medication use, i.e., ivermectin and 108 More public outreach is needed to raise awareness of the benefits of treatment for 111 COVID-19. We found that people who were more aware about treatment for COVID-19 112 were more likely to seek medical advice or therapy. Efforts to increase awareness might 113 increase early treatment for SARS-CoV-2 infection. Additionally, those who were 114 contacted by a health professional were more likely to seek treatment or medical advice 115 for COVID-19. Increased outreach with treatment facilitation from medical professionals 116 and/or public health staff to those with newly detected SARS-CoV-2 infections, 117 particularly among those at higher-risk of complications, might also be helpful. To the participants that donated their time. 130 131 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 14, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 14, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 14, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 14, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 14, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 14, 2022. Antibody Combination to Prevent Covid-19 Early Treatment for Covid-19 with 136 SARS-CoV-2 Neutralizing Antibody Sotrovimab Molnupiravir -A Step toward Orally Bioavailable Therapies for Covid-139 Effect of early treatment 141 with fluvoxamine on risk of emergency care and hospitalisation among patients with 142 COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health Covid-19: Early studies give hope omicron is milder than other 145 variants Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of 147 serious illness, company reports